The Effects of BRCA1 and BRCA2 Promoter Methylation on Clinicopathological Characteristics and Clinical Outcomes in HGSOC
Cells · 01.02.2026 · 15 (3) · 277
DOI: 10.3390/cells15030277 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, online erschienen am 01.02.2026. Verfasst von Katarina Živić und 5 weiteren Autor:innen. Beteiligte Einrichtung: Experimental Oncology Department, Institute for Oncology and Radiology of Serbia, 11040 Belgrade, Serbia. Hauptthemen laut MEDLINE: DNA Methylation, Promoter Regions, Genetic, BRCA2 Protein, BRCA1 Protein. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministarstvo Prosvete, Nauke i Tehnološkog Razvoja, Ministry of Education, Science, and Technological Development.
Abstract (Originalsprache)
Ovarian cancer is a highly lethal disease. Tumors with a deficiency in the homologous recombination repair pathway (HRD) resulting from mutations in BRCA1/2 genes have a favorable response to platinum-based chemotherapy and targeted therapy with PARP inhibitors (PARPi) mediated by synthetic lethality. Promoter methylation of BRCA1/2 genes was previously associated with HRD, but little is known about whether it translates to clinical benefit. Here, we evaluated the prevalence of BRCA1/2 promoter methylation in HGSOC patients from Serbia and examined their clinicopathological characteristics and the effect on progression-free and overall survival. Using methylation-specific PCR, we screened for hypermethylation in the promoter region of BRCA1/2 genes in a cohort of 244 patients. We found fully methylated BRCA1 and BRCA2 promoter in 4.1% and 0.45% of patients, and 23.36% and 11.21% intermediately methylated cases, respectively. Full BRCA1/2 promoter methylation was significantly associated with younger age of onset (55 and 58 years, respectively) compared to BRCA1/2-mutated cases, suggestive of BRCAness phenotype. However, in the exploratory analysis of 68 patients with clinical follow-up, we did not find a strong survival advantage for BRCA1/2 methylated over BRCA1/2-intact cases, yet more moderate effects cannot be ruled out due to the cohort size.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Experimental Oncology Department, Institute for Oncology and Radiology of Serbia, 11040 Belgrade, Serbia.
- Clinic for Medical Oncology, Department for Breast Tumors and Gynecologic Malignances, Institute for Oncology and Radiology of Serbia, 11000 Belgrade, Serbia.
- Medical Genomics, Cancer Biology Department, UCL Cancer Institute, University College London, London WC1E 6DD, UK.
ORCID-Profile: Katarina Živić, Milica Nedeljković, Radmila Janković, Miljana Tanić
Förderung
- Ministarstvo Prosvete, Nauke i Tehnološkog Razvoja
- Ministry of Education, Science, and Technological Development
Zitieren
APA
Živić, K., Boljević, I., Nedeljković, M., Matović, M., Janković, R., & Tanić, M. (2026). The Effects of BRCA1 and BRCA2 Promoter Methylation on Clinicopathological Characteristics and Clinical Outcomes in HGSOC. Cells, 15(3), 277. https://doi.org/10.3390/cells15030277
Vancouver
Živić K, Boljević I, Nedeljković M, Matović M, Janković R, Tanić M. The Effects of BRCA1 and BRCA2 Promoter Methylation on Clinicopathological Characteristics and Clinical Outcomes in HGSOC. Cells. 2026;15(3):277. doi:10.3390/cells15030277
BibTeX
@article{ivi2026,
author = {Živić, Katarina and Boljević, Ivana and Nedeljković, Milica and Matović, Milana and Janković, Radmila and Tanić, Miljana},
title = {The Effects of BRCA1 and BRCA2 Promoter Methylation on Clinicopathological Characteristics and Clinical Outcomes in HGSOC},
journal = {Cells},
year = {2026},
volume = {15},
number = {3},
pages = {277},
doi = {10.3390/cells15030277}
}
EUVIMED